The biotechnology sector stands at an inflection point. After weathering pandemic-era upheavals and navigating a turbulent funding environment, a new generation of biotech startups is emerging with transformative technologies that extend far beyond traditional drug development. These companies are tackling some of healthcare’s most intractable challenges—from non-invasive diagnostics for conditions